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In the face of the current Neonatal Abstinence Syndrome (NAS) epidemic, there is
considerable variability in the assessment and management of infants with NAS. In
this manuscript, we particularly focus on NAS assessment, with special attention given
to the popular Finnegan Neonatal Abstinence Score (FNAS). A major instigator of the
problem of variable practices is that multiple modified versions of the FNAS exist and
continue to be proposed, including shortened versions. Furthermore, the validity of
such assessment tools has been questioned, and as a result, the need for better tools
has been suggested. The ultimate purpose of this manuscript, therefore, is to increase
researchers’ and clinicians’ understanding on how to judge the usefulness of NAS
assessment tools in order to guide future tool development and to reduce variable
practices. In short, we suggest that judgment of NAS assessment tools should be
made on a clinimetrics viewpoint as opposed to psychometrically. We provide examples, address multiple issues that must be considered, and discuss future tool development. Furthermore, we urge researchers and clinicians to come together, utilizing their
knowledge and experience, to assess the utility and practicality of existing assessment
tools and to determine if one or more new or modified tools are needed with the goal of
increased agreement on the assessment of NAS in practice.
Keywords: Finnegan Neonatal Abstinence Score, formative model, Neonatal Abstinence Syndrome Score,
predictive accuracy, reflective model

INTRODUCTION
The number of infants developing Neonatal Abstinence Syndrome (NAS) is reaching epidemic
proportions with increasing number of affected infants receiving pharmacotherapy and increasing
length of stay in hospital (1–4). Therefore, there has been much research recently addressing the
assessment and management of infants with NAS. Unfortunately, there is considerable variability
in practice with respect to both of these aspects (2, 5–8). Inherently, this implies an apparent lack
of agreement among researchers and clinicians in terms of best methods.
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In this manuscript, we focus on the assessment of infants
with NAS. Multiple assessment tools have been developed and
are in use, with the Neonatal Abstinence Syndrome Score, also
known as the Finnegan Neonatal Abstinence Score (FNAS), being
the most commonly used (5, 7, 9–12). However, the FNAS has
been modified multiple times and is not used in exactly the same
manner at every institution (5, 13). For instance, the MOTHER
NAS score (MNS) (14, 15) made considerable revisions to the
FNAS and may be increasing in popularity.
Due to the existence of multiple assessment tools that are
implemented in practice, it is apparent that researchers and
clinicians have not come to a common agreement on how to best
assess NAS. Therefore, we address how to view the theoretical
modeling framework for NAS from which assessment tools
arise. Specifically, we contrast viewpoints based on psychometric
(16–21) and clinimetric (17–19, 22) principles, concluding that
NAS assessment tools should be viewed clinimetrically. We hope
that conveying this modeling framework will give researchers
and clinicians a realistic construct on how to properly judge NAS
assessment tools, as utilizing a psychometric viewpoint will only
lead to the conclusion that existing tools are invalid (21, 22).
Ultimately, we hope that with this increased understanding on
how to view NAS assessment, future work on creating or modifying assessment tools will lead to improved and standardized
NAS assessment and thus management.
In the following section, we give relevant details on theoretical models corresponding to psychometric and clinimetric
viewpoints, respectively, with regards to NAS assessment. We
argue that a clinimetric-based formative model (17–19, 22)
should be preferred, and then discuss how to judge tools and give
examples from the literature. Finally, we provide a discussion
on future tool development, followed by concluding remarks.

Figure 1 | Visual and mathematical representations of a generic
psychometrics-based reflective model in which items X1, X2, and X3 are
caused by and hence are reflections of the hypothetical construct θ. Each
item has its own equation in which the influence of θ is denoted by λ, and the
items may have measurement error, e. The items are expected to be strongly
correlated due to the influence θ has on each one. Note that the number of
items is not restricted, and a scenario with three items was chosen for
simplicity.

PSYCHOMETRIC- AND CLINIMETRICBASED MODELS FOR NAS ASSESSMENT

Figure 2 | Visual and mathematical representations of a psychometricsbased reflective model in which crying, general convulsions (GC), mottling,
etc. are caused by and hence are reflections of neonatal abstinence
syndrome (NAS). Each symptom has its own equation in which the influence
of NAS is denoted by λ, and the symptoms may have measurement error, e.
The symptoms are expected to be strongly correlated due to the influence
NAS has on each one.

Psychometrics—Reflective Model

Psychometric properties are regularly emphasized in practice
(22), and hence, a reflective model (18, 19) is often used as the
default to determine the validity of an assessment tool. Figures 1
and 2 demonstrate a generic reflective model and an assumed
reflective model for NAS, respectively. Applying this model to
NAS, it is assumed that NAS causes each item to present, and
therefore, items should be a reflection of NAS and thus should be
highly correlated; i.e., items should have good internal consistency or reliability (17–19). As a result, equal weighting of items
is preferred (18, 23).

a modeled severity of NAS. Figure 4 specifically depicts the
FNAS, which applies different numerical weighting for crying, general convulsions, mottling, etc. due to their perceived
differing influences on NAS severity. In practice, the modeled
severity may not be the true severity, implying a degree of
discrepancy, also known as the disturbance, between the model
and the truth. See, for instance (17–19), for specific details on
formative models.

Clinimetrics—Formative Model

Generic and NAS-based representations of formative models
arising from clinimetrics-based reasoning are given in Figures 3
and 4, respectively. With this model, the items are not required
to be correlated, and each item contributes, with potentially
varying magnitudes, toward NAS severity (22). Specifically, the
weights depicted in Figures 3 and 4 can vary in value according
to item impact, and the weighted items are summed to form
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Which Theoretical Modeling Framework
Works Best for Judging NAS Assessment?

Table 1 provides a concise comparison of reflective and formative
models. Evidence has shown that NAS assessment tools do not
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are quite variable across and within infants (13, 14, 21, 24), and
thus do not reflect NAS to the same degree. As a result, Jones
et al. (20) found via low Cronbach’s alphas on the FNAS and
MOTHER NAS scale that not all items are highly correlated, and
Bada et al. (25) also found via odds ratios that not all items are
highly interrelated. We note that Cronbach’s alpha is a measure
of the degree of correlation among a group of items in order to
assess internal consistency (26).
The signs of NAS, or symptoms if truly arising from NAS,
build up NAS severity. Furthermore, clinical reality is that certain
symptoms are more critical than others when determining the
severity of NAS, and these symptoms and their severity may not
highly correlate. Therefore, the formative modeling approach
should be preferred as it provides a clinically meaningful basis
on which NAS assessment tools can be judged. This approach
also provides flexibility in that information other than symptom
severity can be employed.

Figure 3 | Visual and mathematical representations of a generic
clinimetrics-based formative model in which items X1, X2, and X3 combine to
form the true hypothetical construct θTrue. The disturbance term represents
the influence of all other factors besides X1, X2, and X3 on θTrue. The numerical
weights applied to the items in the assessment tool are represented by b1,
b2, and b3. Note that the number of items is not restricted, and a scenario
with three items was chosen for simplicity.

JUDGING NAS ASSESSMENT VIA A
FORMATIVE MODELING FRAMEWORK
General Approach

An ideal approach to obtaining a NAS assessment tool based
on a formative approach would be to conduct an empirical
study utilizing a large amount of clean or robust data from the
target population, and to use that data to determine which items
should be incorporated within the resulting tool and how much
weight to assign each item. The primary interest in using tools
to assess NAS severity is to determine when pharmacologic
treatment is needed. Therefore, if we were able to obtain in this
hypothetical study accurate data on when pharmacologic treatment is needed, logistic regression modeling could be employed
to obtain estimated weights (see mathematical models presented
in Figures 3 and 4) which indicate the importance of each
item. The resulting tool could then be used on a separate large
dataset of clean or robust data in order to judge and (hopefully)
validate the predictive accuracy of the tool. An example of such
an approach is the derivation of the Score for Neonatal Acute
Physiology—Perinatal Extension (27).
Unfortunately, there is no way to determine true NAS severity
and thus the need to treat, and therefore, we cannot judge tools
based on their true predictive accuracy. As a result, assessment
tools will need to be judged based on existing knowledge about
NAS severity; i.e., we need to use knowledge from up-to-date
research and clinical experience to make an educated guess as
to what the ideal model for severity should look like. Essentially,
judgments will need to be based on face validity (22), and
we want a tool based on utility (e.g., good perceived predictive accuracy, or low disturbance based on Figures 3 and 4),
practicality, and “clinical common sense” (22). Unfortunately,
different people will have different judgments with respect to
these considerations.
Specific judgments on a tool should be made with respect to
three steps used to create an assessment tool based on a formative model (17). The first two steps consist of determining the
potential variables to form the tool and ultimately deciding

Figure 4 | Visual and mathematical representations of a clinimetrics-based
formative model in which crying (EC, excessive crying; CC, continuous
crying), general convulsions (GC), mottling (M), etc. combine to form
Neonatal Abstinence Syndrome (NAS) severity. The disturbance term
represents the influence of all factors not accounted for by the given
assessment tool. The numerical weights applied to the corresponding items
in the assessment tool are represented by bEC, bCC, bGC, and bM. In the visual
representation, bC is equivalent to either bEC or bCC, depending on the severity
of crying.

Table 1 | A comparison of reflective (psychometrics) and formative (clinimetrics)
models.
Aspect

Reflective model

Formative model

Item role

All items are influenced by
All items build up
and, therefore, reflect Neonatal NAS severity
Abstinence Syndrome (NAS)

Item correlation All items are highly correlated
(internal reliability)

Items do not need
to be correlated

Item weighting

Unequal weighting, depending
on perceived impact the item
has on NAS severity

Equal weighting

coincide with a reflective model. Admittedly, NAS can initially
be thought of in terms of a reflective model, as NAS causes
symptoms, and thus items in the FNAS, for instance, to present.
However, the occurrence, severity, and duration of symptoms
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via formative modeling approaches out of necessity. For instance,
Finnegan et al. (9, 10) used the three steps as just discussed.
In brief, common symptoms were chosen based on the literature
and experience, and weights assigned to each item were chosen
based on pathologic significance. Furthermore, the treatment
cutoff was chosen based on experience.
The fact that multiple modified versions of the FNAS exist,
and that not even treatment cutoff scores are used consistently
across institutions (5, 6), demonstrates the fact that people have
formatively judged the FNAS and have determined it could use
change. Multiple reasons for this exist. As time goes on, our
knowledge with respect to NAS improves, and therefore, the way
true NAS severity is perceived may change, thus alternating the
way we want to model the construct of NAS severity. For instance,
the MNS was created by Jansson et al. (14) to improve upon the
FNAS. Both irritability and failure to thrive, based on weight loss,
were added whereas some items were removed or combined, for
instance, due to overlap. Furthermore, the FNAS is lengthy and
clinicians may desire a shorter tool (28) that is more practical and
potentially more reliably scored, and therefore, shortened scores
have been proposed (29). Even a short functional assessment
approach has been developed which is based on feeding, sleeping, and ability to console when crying (30). We note that, unlike
with a reflective model, heterogeneity of items in the assessment
tool is clinically ideal as the use of correlated items unnecessarily
adds time and complexity to scoring in practice.
An empirical approach that has been taken to formatively
judge a NAS assessment tool, including its treatment cutoff
value(s), is the use of data with the outcome of interest of whether
or not the subject has NAS. Although this outcome is not ideal
and will not provide definitive results because interest is actually
in the unknown true need to treat, results can still be suggestive.
For instance, Zimmerman-Baer et al. (31) studied 102 healthy
neonates and found that the 95th percentile of their scores, from
a version of the FNAS comprised of 28 items, never exceeded
8. Although this suggests that infants not in withdrawal will
tend to have lower FNAS scores, and scores of 8 or above are
mostly in infants who are withdrawing, this does not provide
strong information with respect to the true need to treat infants
in withdrawal. Specifically, interest is with respect to when NAS
infants need to be treated, not if they actually have NAS. However,
these particular results may be suggestive that, although a single
score of 8 to deem treatment is needed is insufficient, an average
of three 8s or two 12s in a row may suffice as adequate treatment
cutoffs for this particular 28 item tool.
Although not a direct factor with respect to judging the
formative nature of a tool, we feel it is important to note that the
inter-rater reliability (IRR) of NAS assessment tools has received
a notable amount of attention, as many items incorporated in
NAS tools are based on subjective judgments. Although scorers
should be trained, they may not always have complete agreement
on the magnitude or occurrence of a clinical sign involved in a
particular tool (23, 24). For instance, IRR coefficients have been
shown, for example, to range from 0.70 (33) to 0.96 (9, 10) with
the FNAS, 0.89 to 0.98 with the Neonatal Withdrawal Inventory
(32), and greater than 0.94 with the MNS (5, 15). Furthermore,
Gomez-Pomar et al. (33) showed that the degree of variance in

which variables, or items, should actually be utilized. The third
step is to determine how much weight should be assigned to each
item. Furthermore, judgments must be made on the value of
pharmacologic treatment cutoff scores, and how to use them. For
instance, the decision to treat when using the FNAS is often based
on whether or not three scores, or their average, of 8 in a row are
observed (9–11), thus also implying two 12s in a row. A summary
of basic considerations, as well as differences in opinion that are
seen in practice, is given in Table 2. Table 2 also summarizes
issues in current practice as discussed in the remainder of this
manuscript.

EXAMPLES
Although many people may not have realized the underlying
theoretical framework, NAS assessment tools have been created
Table 2 | Considerations and obstacles in the evaluation and creation of
Neonatal Abstinence Syndrome (NAS) assessment tools.
Basic considerations
Visualize what the ideal model would look like using knowledge from up-to-date
research and clinical experience
– Consider face validity; i.e., perceived clinical utility
– Consider practicality; e.g., scoring time
– Consider pharmacologic treatment cutoff values based on the ideal model
Differences in opinion
People can have varying opinions on a perceived ideal model. For instance,
opinions can vary with respect to:
– the utility of an item; i.e., is the item needed in the tool, and if so, how much
weight should be assigned to the item?
– the practicality of the item; e.g., does the amount of time it takes to score the
item outweigh its added utility to the tool?
– what treatment cutoff value(s) should be used, and how should they be used?
As a result of differences in opinion, perceived ideal assessment tools will also
differ. This is one reason why new or modified assessment tools continue to be
developed
Issues in current practice
Advances in research and differences in opinion continue to result in different
or modified tools being proposed and used. Examples include:
– additions and reductions in the utilized items, as in the MOTHER NAS score
(14, 15)
– shortened tools
Empirical research on treatment cutoffs has used NAS as the outcome of
interest, as opposed to the true need to treat, and can, therefore, only provide
suggestive evidence with respect to the need for treatment
Judgments should not only consider inter-rater reliability, but also the utility of
items when deciding whether or not to include the item in a tool
Future tools should be developed based on a formative modeling strategy and
can be created by adding or reducing items from existing tools. Furthermore,
other information can be used in conjunction with such tools
Assessment tools based on formative modeling can be developed to encompass
a variety of exposure types
Tools tend to only be developed by a small group of people before being
published and presumably used. Due to likely differences in opinion from other
clinicians and researchers, implementation and ultimately standardization in
practice is unlikely
To help standardize NAS assessment, experts should come together to decide
on the best formative model(s) and ultimately assessment tool(s) to use
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FNAS scores attributable to unreliable scoring is small (≤9.8%
in the studied institutions). Although when viewed from a
psychometric viewpoint, an interobserver reliability of 90% is
desired (21, 34), there may still be enough utility in keeping any
items in the tool that cause lack in IRR as opposed to removing
them. Therefore, judgments should not only consider IRR, but
also the utility of items. For instance, although it may be difficult
to clearly distinguish the cutoffs between mild, moderate, and
severe tremors, incorporation of this item with the chance of
misclassification can still be more useful than not using this item
simply because of this potential difficulty.

hope to obtain the best guidance as practically possible from
these tools (28).
Major contributing factors to the existence of a variety of
NAS assessment tools include the fact that researchers have been
independently judging and creating these tools and differences
in opinion exist. As a result, it is very difficult for any new tool
to be widely assessed and ultimately implemented in practice, as
other clinicians and researchers may not agree with the proposed
tool in terms of its utility and practicality. Therefore, we urge that
a large group of experts in the area of NAS assessment should
come together and pool their knowledge and clinical experience to assess the utility and practicality of existing assessment
tools and to determine if one or more new or modified tools
are needed. If needed, such “best” tools should be formulated
with consideration of both perceived utility and practicality
based on a formative modeling strategy. We suspect there will
never be complete agreement and, therefore, compromises and
ultimately a consensus in terms of the included items and the
assigned weights to each item is likely needed (17). Furthermore,
randomized clinical trials may be warranted to confirm the
superiority of any such tools to existing tools on outcomes of
importance such as length of stay and duration of opioid treatment (13, 38).

FUTURE TOOL DEVELOPMENT
As more is learned about NAS, assessment tools may need to
evolve. Based on a formative modeling approach, new items
and their perceived impacts, via appropriate weights, can be
added to tools, and numerical treatment cutoff values modified
accordingly. Alternatively, items deemed to have little utility
or practicality in the presence of other items can be removed.
We do note that newer information, such as knowledge on genetics and the mother’s prenatal treatment (5), may be difficult to
incorporate into a standard assessment tool. However, research
could be conducted on how to best utilize such information in
conjunction with the tool. For instance, Grossman et al. (30)
recently demonstrated that a simple functional assessment can
work well when combined with other novel strategies for NAS
management.
Formative models can also conform to variations that exist in
practice and that should be considered for future tool development. Presenting NAS symptoms may depend on the type of
opioid causing withdrawal, among other possible factors (6, 13,
21, 35). Furthermore, many infants’ withdrawal can be a result
from exposures to multiple types of drugs, which would not
correspond to a single opioid-based tool. This issue is amplified
when there is also exposure to non-opioids (21, 36). Extending
upon the issue of heterogeneous exposures, variations in the
distributions of exposure types may also exist across different
institutions due to the different populations they care for (33). All
of these variations will contribute to a lack in correlation among
items in as assessment tool, and thus the tool will be deemed
inappropriate if based on a reflective modeling viewpoint.
However, when based on a formative model, a tool is allowed to
encompass the spectrum of opioids. Specifically, this modeling
approach allows us to simultaneously assess symptoms from
different types of exposures, thus building up a case for the need
to treat. This is important because it is clinically irrelevant to
restrict the applicability of a tool to a single exposure type when
in real life we are faced with multidrug-exposed withdrawing
infants (37). We do note, however, that this issue adds a notable
degree of complexity in terms of judging the utility of any such
tool, and multiple tools may be required; e.g., a unique tool for
a single or specific mixture of exposures, or even a unique tool
for institutions observing similar distributions in exposures.
Unfortunately, no existing or future tools will be ideal, but we
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CONCLUSION
There is push in the NAS literature on the need for a new
assessment tool that is psychometrically valid (21). However,
this inherent proposed use of a reflective model does not
correspond to the real-world diversity of NAS manifestations observed in practice and the fact that numerical scores
from an assessment tool do not completely dictate the decision to start pharmacological treatment. Therefore, in this
manuscript, we argue that judgments on, and therefore future
development of, NAS assessment tools should be based on
a formative modeling approach. Such an approach can take
into account the complexity of the presenting symptoms of
NAS, their severity, and potentially the fact that heterogeneity
of symptoms and their severity exists across different types
and mixtures of opioid exposures. Finally, current assessment
tools must be judged using current knowledge and experience,
and judgment can vary in opinion. Therefore, one or more
assessment tools based on a formative model and created
based on the input of a large group of experts may be needed
in order to lead to increased agreement on the assessment of
NAS in practice.
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